UBS raises Vertex stock price target to $615 on kidney drug trial
Covered in this story
What has happened since
- Vertex Pharmaceuticals is down 3.9% since this was published, 22 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
UBS’s $615 target on $VRTX is on the record and being tracked to Sep 2027 (12-month default), scored on the close that day.
UBS’s track record →Analyst targets on Vertex Pharmaceuticals
- H.C. Wainwright: $515 → $641 by Sep 2027 · Buy via Investing.com
- BMO Capital Markets: $515 → $600 by Sep 2027 · Outperform via Investing.com
- Wolfe Research: $524 → $562 by Aug 2027 · Outperform via Investing.com
Published targets verified against independent reporting and tracked to their dates. Not recommendations from Dalsna Finance.
Call it yourself
No member calls on $VRTX yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Vertex Pharmaceuticals →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.